Congela Biocosmetics, LLC., a biocosmetic company formulating precision, regenerative hair and skin products, announced today the acquisition of the JuveXO® brand and product line. This strategic acquisition accelerates the development of innovative biocosmetic products and will reinvent the future of aesthetics. Brian Pla steps up as the President for Congela Biocosmetics, where he will continue to lead the company, supported by his existing accomplished scientific and management team.
“Congela’s vision is to pioneer and set the global standard in biocosmetics by providing diverse and continually innovative skincare products,” says Brian Pla. “This strategic acquisition of JuveXO®, allows us to sustainably pursue and achieve this vision further expanding on Restem Group’s extensive cell-based product history,” adds Pla.
Congela Biocosmetics now becomes the sole distributor of JuveXO®, a leading topical exosome serum backed by over a decade of scientific research. Created upon the foundation of innovative stem cell research, JuveXO® provides consumers with an alternative to improve the skin’s appearances in areas of common skin concerns like fine lines, wrinkles, redness, and inflammation, as well as improve the appearance of dull, damaged, and thinning hair. When used in conjunction with microneedling or fractional devices, JuveXO® penetrates deep into the skin to provide transformative regenerative results.
Congela Biocosmetics is a subsidiary of Restem Group, a leader in cellular innovation that offers substantial support to propel Congela Biocosmetics into the future of aesthetics. With the support of the Restem Group, Congela will heighten its product line, providing consumers and practitioners with the safest, most efficacious, and most innovative solutions to their skin concerns.
“Our vision is to advance science using our expertise in stem cells and riding on the incredible results already created by Congela within the biocosmetic sector,” stated Rafael Gonzalez, Ph.D, Founder of Restem and Chief Scientific Officer of Congela Biocosmetics. “Witnessing the transformative potential of JuveXO®, we are very excited about the acquisition and the monumental opportunity of Congela Biocosmetics,” added Dr. Gonzalez.
The future of Congela Biocosmetics is bright as it rapidly gains market share and continues to expand its product line to provide consumers and practitioners with all-encompassing cosmetic options for common skin and hair concerns, both in office and at home. Congela is launching a series of webinars to discuss the future of exosomes in biocosmetics, and will be in attendance at various aesthetic and cosmetic events throughout 2024.
